Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
AVXL · against 1,336 other Healthcare companies
Ranked #857 of 1,337 · scores higher than 33% of peers
Bars: peers in each 10-point band of the valuation score133 peers with a valuation score of 30–39, including AVXL · Click a bar to see the companies
Mainly because of its free cash flow yield and earnings yield, which are weaker than most Healthcare peers.
| Metric | AVXL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | -11.7% | 1.5% | 18% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | Not reported | 4.2% | — | — | 50% |
| Free cash flow yieldHigher is better · 711 reported | -26.3% | -1.0% | 11% | 20% | |
| Book yieldHigher is better · 1,306 reported | 101.1% | 37.9% | 87% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 857 | 23M USD | 33 | ||
| 857 | 642M USD | 33 | 46 | |
| 857 | 1.2B USD | 33 | ||
| 857 | 389M USD | 33 | 33 | |
| 857 | 111M USD | 33 | ||
| 857 | 186M USD | 33 | 43 | |
| 857 | 257M USD | 33 | 55 | |
| 857 | 274M USD | 33 | 57 | |
| 857 | 6.1B USD | 33 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score